FSDC To Keep Close Vigil On Illegal Influx Of Narcotics

Jaipur, 4 Jan 2024: The information of supplies made by Narcotic Drugs and Psychotropic Substances (NDPS) drug manufacturing companies established outside Rajasthan to the distributors of the state will be collected from drug controllers of the respective states.

If any difference is found in the quantity of supply, sale and stock, then action will be taken against all the parties concerned including the company. The stock of NDPS medicines should be limited on the lines of Uttar Pradesh and Uttarakhand.

The health department took the decision to ensure that the NDPS drugs should not be used for addiction, and it should only be used for the treatment of mental health issues.

The health department is taking necessary steps to save the young generation of the state from drug addiction and to realise the resolve of drug-free Rajasthan.

A health department official said in the meeting of the concerned departments on Tuesday, directions have been issued to strictly stop the illegal trade of narcotics and psychotropic drugs influx in the state.

The police and drug control department officials should ensure strict action against illegal sale of NDPS medicines. Effective monitoring of the sale of NDPS medicines should be done by licenced wholesale and retail drug dealers. If any seller is found selling such medicines without a licence, then action should be taken against him under the sections of NDPS Act, said a health department official.

If any licenced medicine seller is found involved in illegal NDPS drug trade, then a letter should be written to the Rajasthan Pharmacy Council to cancel the licence and registration of that shop and the pharmacist working at the shop. The social justice and empowerment department should take action against unregistered de-addiction centres.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’